CADL vs GNLX
CADL: Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic cell death within solid tumors. GNLX: Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and trigger personalized anti-tumor immune responses.
Side-by-side fundamentals
| Metric | CADL | GNLX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.09 | $2.96 | |
| Market cap as of 2026-07-23 | $739M | $131M | |
| Net margin as of 2026-07-23 | -15156.5% | -115587.5% | CADL higher |
| Operating margin as of 2026-07-23 | -28000.8% | -117650.0% | CADL higher |
| ROE as of 2026-07-23 | -60.4% | -174.6% | CADL higher |
| ROA as of 2026-07-23 | -41.3% | -123.6% | CADL higher |
| Debt / equity as of 2026-07-23 | 0.34 | 0.00 | GNLX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -91.0% | |
| Revenue CAGR (3y) SEC XBRL | +0.0% | -91.0% | CADL higher |
| Beta as of 2026-07-23 | -0.46 | 0.57 | |
| 1-year return as of 2026-07-22 close | +55.6% | -17.7% | CADL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.